[HTML][HTML] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes, N Pemmaraju… - …, 2021 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes… - …, 2021 - einstein.elsevierpure.com
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent
and venetoclax regimens — Albert Einstein College of Medicine Skip to main navigation Skip to …
and venetoclax regimens — Albert Einstein College of Medicine Skip to main navigation Skip to …
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes, N Pemmaraju… - …, 2021 - profiles.wustl.edu
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating
agent and venetoclax regimens — Research Profiles at Washington University School of …
agent and venetoclax regimens — Research Profiles at Washington University School of …
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
A Maiti, CR Rausch, JE Cortes, N Pemmaraju… - …, 2021 - europepmc.org
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
[引用][C] Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes, N Pemmaraju… - Haematologica, 2020 - cir.nii.ac.jp
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating
agent and venetoclax regimens | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
agent and venetoclax regimens | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating
agent and venetoclax regimens Outcomes of relapsed or refractory acute myeloid leukemia …
agent and venetoclax regimens Outcomes of relapsed or refractory acute myeloid leukemia …
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes… - …, 2021 - augusta.elsevierpure.com
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating
agent and venetoclax regimens — Augusta University Research Profiles Skip to main navigation …
agent and venetoclax regimens — Augusta University Research Profiles Skip to main navigation …
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes… - …, 2021 - mdanderson.elsevierpure.com
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating
agent and venetoclax regimens — MD Anderson Cancer Center Skip to main navigation Skip to …
agent and venetoclax regimens — MD Anderson Cancer Center Skip to main navigation Skip to …
[HTML][HTML] Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes, N Pemmaraju… - …, 2021 - haematologica.org
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
[HTML][HTML] Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes, N Pemmaraju… - …, 2021 - haematologica.org
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …